In vitro

MercachemSyncom Closes the Acquisition of Admescope

Retrieved on: 
Monday, November 9, 2020
Biotechnology, Health, Science, Pharmaceutical, Research, Alternatives to animal testing, In vitro, In vivo, Tolonen, Science, MercachemSyncom, Admescope

The acquisition will give MercachemSyncom significantly expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for pre-clinical and early clinical R&D projects and seamless integration with the existing medicinal, synthetic and development chemistry capabilities of MercachemSyncom.

Key Points: 
  • The acquisition will give MercachemSyncom significantly expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for pre-clinical and early clinical R&D projects and seamless integration with the existing medicinal, synthetic and development chemistry capabilities of MercachemSyncom.
  • Eelco Ebbers, CEO of MercachemSyncom, commented, We are extremely happy to be able to welcome our colleagues at Admescope to MercachemSyncom.
  • The addition of Admescope to MercachemSyncom caps an extremely exciting year for our company.
  • Ari Tolonen, CEO of Admescope, added, "We are thrilled to continue our successful growth as a part of MercachemSyncom.

Magnostics is Co-Developing and Launching a Viral RNA Extraction Kit for Medium Throughput Processing of COVID-19 Samples for Detection Using RT-PCR

Retrieved on: 
Thursday, November 5, 2020
Life sciences, Drug discovery, High-throughput screening, Pharmaceutics, Health sciences, Natural sciences, RNA extraction, In vitro

Magnostics is leading a consortium of University and National Researchers to develop and launch Viral RNA Extraction Kits for detection of COVID-19.

Key Points: 
  • Magnostics is leading a consortium of University and National Researchers to develop and launch Viral RNA Extraction Kits for detection of COVID-19.
  • High rates of testing across the world are key in enabling us to safely navigate our way out of the pandemic.
  • This important demonstration forms the basis for Magnostics Ltd to develop a CE marked 'lab-in-box' kit for the medium throughput manual extraction of viral RNA from clinical samples.
  • Our magnetic nanomaterials are essential components that are used in-vitro diagnostics (IVD), bioseparation, and high throughput screening (HTS).

OraSure’s OMNIgene®·ORAL Collection Device Receives FDA Emergency Use Authorization for SARS CoV-2

Retrieved on: 
Monday, October 19, 2020
Medicine, Clinical medicine, Medical specialties, Alternatives to animal testing, Medical tests, COVID-19 testing, Coronavirus disease, Food and Drug Administration, Oragene, In vitro, Genetic testing, Blood test

With this FDA authorization, OMNIgeneORAL devices can be used for the self-collection, transport and laboratory testing of saliva specimens suspected of containing SARS-CoV-2 ribonucleic acid (RNA).

Key Points: 
  • With this FDA authorization, OMNIgeneORAL devices can be used for the self-collection, transport and laboratory testing of saliva specimens suspected of containing SARS-CoV-2 ribonucleic acid (RNA).
  • This EUA follows the CE marking of OMNIgeneORAL (OME-505) for in vitro diagnostic use, including for COVID-19 testing, in the European Union.
  • The OMNIgeneORAL device has been included in EUAs granted to Clinical Reference Laboratory (CRL) and P23.
  • The Company's OrageneDx and ORAcollectDx product lines are the first and only FDA 510(k) cleared saliva-based DNA collection devices for in vitro diagnostic use.

The Evolution of Diagnostic Capabilities Underscores the Fight Against Viral Infections

Retrieved on: 
Thursday, October 8, 2020
Medical tests, Medicine, Biology, Biotechnology, Molecular diagnostics, Life sciences, IVD, In vitro, Diagnosis

There are also various types of diagnostic methods including In Vitro Diagnostics (IVD), Point of Care (POC), Molecular diagnostics, genomic diagnostics and others.

Key Points: 
  • There are also various types of diagnostic methods including In Vitro Diagnostics (IVD), Point of Care (POC), Molecular diagnostics, genomic diagnostics and others.
  • During a pandemic, many states and regions are experiencing a shortage of tests, which is a serious obstacle in the fight against the spread of the viral infections.
  • 'We are preparing to meet the significant need for mobile testing solutions nationwide so that we can open American communities safely.
  • This Mobile Labs network will add a key tool in our battle with COVID-19 heading into the fall and winter months.'

The Evolution of Diagnostic Capabilities Underscores the Fight Against Viral Infections

Retrieved on: 
Thursday, October 8, 2020
Medical tests, Medicine, Biology, Biotechnology, Molecular diagnostics, Life sciences, IVD, In vitro, Diagnosis

There are also various types of diagnostic methods including In Vitro Diagnostics (IVD), Point of Care (POC), Molecular diagnostics, genomic diagnostics and others.

Key Points: 
  • There are also various types of diagnostic methods including In Vitro Diagnostics (IVD), Point of Care (POC), Molecular diagnostics, genomic diagnostics and others.
  • During a pandemic, many states and regions are experiencing a shortage of tests, which is a serious obstacle in the fight against the spread of the viral infections.
  • 'We are preparing to meet the significant need for mobile testing solutions nationwide so that we can open American communities safely.
  • This Mobile Labs network will add a key tool in our battle with COVID-19 heading into the fall and winter months.'

Preclinical Studies Reveal Balloon-Based Drug Delivery to Be Critically Dependent on Coating Micro-Morphology, Suggesting a Paradigm for Accelerated Treatment Optimization

Retrieved on: 
Wednesday, September 30, 2020
Science, Cardiology, Biotechnology, Research, Surgery, Health, Medical devices, Clinical trials, Pharmaceutical industry, Alternatives to animal testing, Drug discovery, In vitro, Preclinical development, In vivo, Health sciences, Health, Natural sciences

CBSET has spent years of investment in the development of novel preclinical methods that enable the study of drug uptake from DCBs.

Key Points: 
  • CBSET has spent years of investment in the development of novel preclinical methods that enable the study of drug uptake from DCBs.
  • Despite the availability of 5-year clinical studies on drug coated balloons (DCB), not much was known on how and where these devices deliver their drug load.
  • We can now begin to differentiate drug coated balloons based not simply on drug payload, excipient or dissolution rate, but also on net tissue spatial delivery.
  • We provide top-tier research with operational expertise by combining in vivo studies, in vitro studies, computational and 3D modeling, and complex histopathology into one integrated paradigm.

Sojournix Presents Data at NAMS Showing SJX-653 Exhibits Potent NK3 Antagonist Profile Across Nonclinical and Initial Clinical Studies in Men and Postmenopausal Women

Retrieved on: 
Monday, September 28, 2020
Health, Hospitals, Clinical trials, General Health, Pharmaceutical, Biotechnology, Drugs, RTT, Medical specialties, Human development, Diketones, Pregnanes, Progestogens, Hot flash, North American Menopause Society, Menopause, In vitro, Medroxyprogesterone acetate

Sojournix , a clinical-stage biopharmaceutical company developing transformative medicines for womens health and neuroendocrine disorders, announced today a poster presentation of data showing SJX-653 exhibits a potent NK3 antagonist profile across in vitro studies, in vivo models, and initial clinical studies in men and postmenopausal women.

Key Points: 
  • Sojournix , a clinical-stage biopharmaceutical company developing transformative medicines for womens health and neuroendocrine disorders, announced today a poster presentation of data showing SJX-653 exhibits a potent NK3 antagonist profile across in vitro studies, in vivo models, and initial clinical studies in men and postmenopausal women.
  • The results were presented in a scientific poster at the 2020 Virtual Annual Meeting of the North American Menopause Society (NAMS).
  • SJX-653 is a novel, potent, highly-selective NK3 antagonist in development as a non-hormonal once-daily treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, commonly called hot flashes.
  • The progression of SJX-653 into clinical studies enabled a translational assessment of the exposure/response relationship across in vitro models, in vivo studies in guinea pigs and dogs, and clinical studies in men and postmenopausal women, said Phil Graham PhD, Chief Development Officer at Sojournix.

Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin™: The First Immune Based Suicide Prevention Biological Therapy

Retrieved on: 
Thursday, September 24, 2020
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Alternatives to animal testing, In vitro, Immunotherapy, Induced stem cells, Stem cell secretome

Neuroleukin functions by unleashing therapeutic activities from specific cells of the patient's own blood in a manner to selectively block brain chemicals associated with suicide.

Key Points: 
  • Neuroleukin functions by unleashing therapeutic activities from specific cells of the patient's own blood in a manner to selectively block brain chemicals associated with suicide.
  • The Company has demonstrated in vitro and in vivo proof of concept and is planning pilot clinical trials.
  • Therapeutic Solutions International is approaching neurological diseases with a focus on regeneration.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

RELX Opens Bioscience Lab to Enhance Global E-Cigarette Research

Retrieved on: 
Thursday, September 17, 2020
Consumer electronics, Retail, Technology, Other Technology, Tobacco, Research, Science, RELX, Toxicology, In vitro, Companies of the United Kingdom, Companies

At the RELX Lab Open Day, RELX also announced its plan to establish a 1+4 scientific research approachi.e.

Key Points: 
  • At the RELX Lab Open Day, RELX also announced its plan to establish a 1+4 scientific research approachi.e.
  • E-cigarettes are sometimes viewed with suspicion because we have incomplete knowledge, said Yilong Wen, RELX Co-founder and Head of Science, Research and Development and Supply Chain, The RELX bioscience labs mission is to explore the unknown.
  • To ensure the reliability and quality of RELX products, RELX established a chemical and physical laboratory in 2018.
  • RELX started its groundbreaking research on the toxicological and pharmacological study on its products in 2019, and the new bioscience lab will focus on vivo and in vitro tests, as well as conduct pre-clinical safety assessments in 2020.

In Vitro Toxicity Testing Market by Product, Toxicity Endpoints, Industry COVID-19 Impact - Global Forecast to 2025

Retrieved on: 
Tuesday, September 15, 2020
Toxicology, Laboratory techniques, Natural sciences, Physical sciences, Biochemistry, Branches of science, In vitro toxicology, In vitro, Assay

7 In Vitro Toxicology Testing Market, by Product & Service

Key Points: 
  • 7 In Vitro Toxicology Testing Market, by Product & Service
    7.4.3.1 Cell-Based Assays Are Cost-Effective, Owing to Which They Are Witnessing Increasing Adoption in Drug Discovery
    7.4.4.1 Receptor-Binding Assays Are Well-Suited for High-Throughput Formats, a Key Factor Driving the Adoption of These Products
    8 In Vitro Toxicology Testing Market, by Toxicity Endpoint & Test
    8.8.1 Validated Non-Animal Methods Are Used to Evaluate the Photosafety of Cosmetics, Pharmaceuticals, & Chemicals
    9 In Vitro Toxicology Testing Market, by Technology
    10 In Vitro Toxicology Testing Market, by Industry
    11 In Vitro Toxicology Testing Market, by Method
    12 In Vitro Toxicology Testing Market, by Region